Free tool
FAERS Monitor: Cayston
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050814 or its brand name (Cayston, Aztreonam). Reports on generic versions are filed under their own applications.
Reports
6,555
Serious
4,815
73% of reports
Hospitalization
3,276
Death reported
854
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- infective pulmonary exacerbation of cystic fibrosis851
- dyspnoea432
- hospitalisation394
- off label use365
- cough353
- cystic fibrosis287
- pneumonia279
- death277
- pyrexia257
- infection249
- condition aggravated205
- haemoptysis187
- drug ineffective175
- headache175
- nausea165
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 25 |
| 2006 | 34 |
| 2007 | 20 |
| 2008 | 20 |
| 2009 | 27 |
| 2010 | 48 |
| 2011 | 68 |
| 2012 | 122 |
| 2013 | 327 |
| 2014 | 340 |
| 2015 | 294 |
| 2016 | 360 |
| 2017 | 384 |
| 2018 | 617 |
| 2019 | 1,172 |
| 2020 | 968 |
| 2021 | 413 |
| 2022 | 281 |
| 2023 | 295 |
| 2024 | 303 |
| 2025 | 219 |
| 2026 | 196 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,604 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infective pulmonary exacerbation of cystic fibrosisSignal | 851 | 594.4 | 554.8 | 425,001 |
| cystic fibrosisSignal | 287 | 175.4 | 156.1 | 47,027 |
| haemoptysisSignal | 187 | 21.7 | 18.8 | 3,644 |
| hospitalisationSignal | 394 | 8.2 | 7.5 | 2,514 |
| infectionSignal | 249 | 5.5 | 4.9 | 924 |
| coughSignal | 353 | 4.0 | 3.7 | 815 |
| pneumoniaSignal | 279 | 2.8 | 2.5 | 318 |
| dyspnoeaSignal | 432 | 2.4 | 2.2 | 379 |
| pyrexiaSignal | 257 | 2.4 | 2.1 | 208 |
| condition aggravatedSignal | 205 | 2.2 | 1.9 | 129 |
| off label use | 365 | 1.3 | 1.2 | 32 |
| death | 277 | 1.0 | 0.9 | 0 |
| headache | 175 | 0.9 | 0.8 | 2 |
| nausea | 165 | 0.7 | 0.6 | 28 |
| drug ineffective | 175 | 0.4 | 0.4 | 144 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.